FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
KPV 5mg research peptide vial
Recovery

KPV

α-MSH (11-13) tripeptide

A tripeptide fragment of α-MSH studied in inflammatory-pathway research.

From $50

In stock · ships in 1–2 business days

  • ✓ 99.802% purity (tested)
  • ✓ HPLC + mass-spec tested
  • ✓ View batch COA
  • ✓ Discreet US shipping
anti-inflammatory researchmucosal

Research Summary

KPV is a C-terminal tripeptide of alpha-melanocyte-stimulating hormone, investigated in preclinical research for its role in inflammatory signaling and mucosal models. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

KPV: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is KPV?

KPV is a synthetic tripeptide made of lysine, proline, and valine. It reproduces the last three residues (positions 11 to 13) of alpha-melanocyte-stimulating hormone, or alpha-MSH, a 13-residue peptide with the sequence SYSMEHFRWGKPV [1] [2]. PubChem lists KPV under the names alpha-MSH (11-13) and ACTH-(11-13), since the same three residues also occur in adrenocorticotropic hormone [1].

Alpha-MSH is derived from proopiomelanocortin and has been widely studied for anti-inflammatory and protective effects. A 2008 review explained that one obstacle to studying alpha-MSH in inflammation models is its pigmentary activity, and that KPV attracted interest because it retained anti-inflammatory activity in experimental systems without that pigmentary action [3].

Most published KPV research is cell and rodent work on inflammatory signaling, the intestinal lining, and microbial growth. It is far less studied than larger research peptides, and the bulk of the work comes from a limited number of research groups.

KPV molecular identity
SequenceLys-Pro-Val (KPV)
Length3 amino acids (tripeptide)
OriginC-terminal residues 11 to 13 of alpha-melanocyte-stimulating hormone (alpha-MSH)
Molecular formulaC16H30N4O4
Molecular weight342.43 g/mol
CAS number67727-97-3
PubChem CID125672
Other namesalpha-MSH (11-13), ACTH-(11-13), L-lysyl-L-prolyl-L-valine (PubChem synonyms)

Mechanisms studied

Several mechanisms have been proposed to explain the effects reported in experimental models. None has been confirmed in humans, and the studies below do not all agree on how KPV acts.

Uptake through the PepT1 transporter

PepT1 is a di- and tripeptide transporter normally found in the small intestine and induced in the colon during inflammation. In a 2008 study using human intestinal epithelial cell lines (Caco2-BBE and HT29-Cl.19A) and human Jurkat T cells, KPV was transported into cells by PepT1. At nanomolar concentrations it inhibited activation of NF-kappaB and MAP kinase inflammatory pathways and reduced secretion of pro-inflammatory cytokines after cytokine stimulation [4].

NF-kappaB nuclear import

A 2012 study in immortalized human bronchial epithelial cells (16HBE14o-) reported that KPV inhibited TNF-alpha and virus-induced NF-kappaB signaling and reduced secretion of the chemokines IL-8 and eotaxin. The effect was associated with nuclear import of KPV, stabilization of the inhibitor IkappaB-alpha, and reduced nuclear translocation of the p65 RelA subunit. Competition assays suggested KPV interacted with the importin-alpha3 binding site on p65 [5].

Melanocortin receptor signaling

Whether KPV acts through melanocortin receptors is unsettled. In a 2004 study of human keratinocytes, alpha-MSH, KPV, and related peptides did not raise cyclic AMP, but triggered intracellular calcium signals under specific conditions. In Chinese hamster ovary cells engineered to express the melanocortin-1 receptor (MC1R), KPV raised intracellular calcium [6]. In a mouse colitis study, KPV remained active in mice with a non-functional MC1R, which the authors interpreted as evidence of at least partly MC1R-independent action [7].

Direct antimicrobial activity

In a 2000 study, alpha-MSH and KPV inhibited colony formation of Staphylococcus aureus and reduced viability and germ-tube formation of Candida albicans in vitro, over a broad range of concentrations. The authors linked the effect partly to increased cyclic AMP in the microbes [2]. A 2011 study reported that alpha-MSH (11-13) killed more than 90% of methicillin-sensitive and methicillin-resistant S. aureus cells at micromolar concentrations, depolarizing and permeabilizing bacterial membranes in a manner similar to the full-length hormone [8].

Areas of research

Intestinal inflammation models

Colitis models are the most developed area of KPV research. In the 2008 PepT1 study, KPV given in drinking water reduced the incidence of colitis induced by dextran sodium sulfate (DSS) or trinitrobenzene sulfonic acid (TNBS) in mice, with lower pro-inflammatory cytokine expression [4]. A second 2008 study reported that KPV reduced inflammatory infiltrates and myeloperoxidase activity in DSS colitis and in a T-cell transfer colitis model in mice [7].

Later work focused on delivery systems in rodent models. A 2017 study loaded KPV into hyaluronic-acid-functionalized nanoparticles and reported targeted uptake into colonic epithelial cells and macrophages, with reduced mucosal damage and TNF-alpha in a mouse ulcerative colitis model [9]. A 2023 review placed these findings within broader preclinical research on the melanocortin system in inflammatory bowel conditions [10].

Colitis-associated tumor models

A 2016 mouse study examined the role of PepT1 in colitis-associated tumor formation. KPV reduced tumorigenesis in wild-type mice but had no such effect in mice lacking PepT1, consistent with the transporter-dependent mechanism described above [11].

Oral mucosa models

In a 2021 rat model of chemotherapy-induced oral mucositis, KPV was incorporated into a temperature-sensitive mucoadhesive hydrogel. The authors reported reduced IL-1beta and TNF-alpha, increased IL-10, improved tissue morphology, and antibacterial activity against S. aureus, including in MRSA-infected wounds [12].

Brain injury models

In a 2013 mouse model of traumatic brain injury, a single administration of alpha-MSH (11-13) was followed by a smaller secondary lesion volume, reduced microglial activation by morphology, and less neuronal apoptosis. Expression of the inflammatory markers TNF-alpha and IL-1beta was not reduced [13].

Related tripeptides

KPV is often discussed alongside KdPT, which the 2008 review described as a derivative of KPV corresponding to residues 193 to 195 of interleukin-1beta, and which was also emerging as an anti-inflammatory tripeptide in experimental systems [3]. The two are distinct compounds, and results for one should not be assumed for the other. The same review summarized how the parent hormone, alpha-MSH, affected NF-kappaB activation, adhesion molecule expression, cytokine production, and inflammatory cell migration across animal models of skin, gut, eye, lung, and joint inflammation, which is the background against which KPV research developed [3].

How to read this literature

Several features of the KPV literature limit how far its findings can be generalized. Many studies combined KPV with a delivery vehicle, such as nanoparticles or hydrogels, so the measured effects reflect the formulation as well as the peptide [9] [10] [12]. Inflammation models such as DSS and TNBS colitis differ from each other and from naturally occurring disease, and a substantial part of the intestinal work comes from a small number of laboratories [4] [10]. Concentrations tested in cell and microbial assays spanned a very wide range, from femtomolar to micromolar, and the mechanisms proposed in epithelial cells, keratinocytes, and microbes are not the same [4] [6] [9].

Open research questions

  • Which receptor or transport pathways account for KPV activity in different cell types, given conflicting evidence on melanocortin receptor involvement [6] [7].
  • Stability and handling of a very small, unmodified tripeptide in biological fluids, which has driven much of the delivery-system research [9].
  • Whether findings from a few rodent model systems replicate across independent laboratories and larger animal models.

State of the human evidence

There is essentially no published human evidence for KPV. A PubMed search for KPV clinical or randomized trials on the review date returned no results, and FDA states that it has not identified any human exposure data on drug products containing KPV [14].

The findings summarized on this page come from cell lines, isolated microbes, and rodent models. They should not be read as evidence of safety or benefit in people, and KPV should be regarded as an investigational research compound.

Regulatory status

  • Not FDA approved. KPV is an unapproved peptide. It is not approved by the U.S. Food and Drug Administration for any human use, and the compounding vote described below does not make it an approved drug [15].
  • Compounding. FDA's list of bulk drug substances that may present significant safety risks (current as of April 22, 2026) includes KPV among substances whose nominations were withdrawn. FDA notes that it has not identified human exposure data for KPV products and lacks important information about safety issues [14].
  • Advisory committee vote. On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, to recommend KPV for the 503A bulks list, evaluated for wound healing and inflammatory conditions. FDA staff had recommended against adding the peptides reviewed. The vote is a non-binding recommendation, FDA is not bound by it, and FDA had not acted on it at the time of this review [15] [16] [17].
  • Sport. KPV is not named individually on the World Anti-Doping Agency 2026 Prohibited List. The list's S0 class covers pharmacological substances with no current approval by any governmental health authority for human therapeutic use [18].

Rejuvatide supplies KPV strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

Every Rejuvatide lot of KPV is tested by an independent laboratory for purity by HPLC and identity by mass spectrometry, and is also tested for endotoxin under USP <85>. The current certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.

KPV is also a component of our Klow Blend, alongside BPC-157, TB-500, and GHK-Cu. Browse all research peptides in this category, or see our BPC-157 and TB-500 research pages.

Storage of lyophilized material

KPV ships as a lyophilized (freeze-dried) powder, which is stable at ambient temperature during transit. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

Certificate of Analysis

Independently tested by Freedom Diagnostics. This is the certificate for the current batch of KPV.

99.802%HPLC purity
Lot 25082508Tested batch

Your browser cannot display the PDF inline. Open the Certificate of Analysis.

KPV FAQ

What is KPV?

KPV is a synthetic tripeptide, Lys-Pro-Val, that reproduces residues 11 to 13 at the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied in preclinical research on inflammatory signaling, intestinal inflammation models, and antimicrobial activity.

How is KPV related to alpha-MSH?

KPV is the last three residues of the 13-residue alpha-MSH peptide. Researchers studied it because it retained anti-inflammatory activity in experimental systems without the pigmentary activity of the full hormone.

Is KPV FDA approved?

No. KPV is not FDA approved for any human use. An FDA advisory committee voted 8 to 6 in July 2026 to recommend it for the 503A compounding list, but that recommendation is non-binding and FDA had not acted on it as of October 12, 2026.

Has KPV been studied in humans?

Essentially no. No published clinical trials of KPV were found in PubMed as of October 2026, and FDA states it has not identified human exposure data for KPV products. Published research is limited to cell and animal models.

How is Rejuvatide KPV tested?

Each lot is tested by an independent laboratory for HPLC purity, mass-spec identity, and endotoxin under USP <85>. The certificates are published on the product page and in the COA library, matched to the lot number on the vial.

Is KPV for human use?

No. Rejuvatide sells KPV for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. PubChem. Msh (11-13), Lys-Pro-Val, Compound CID 125672. National Library of Medicine. Source
  2. Cutuli M, Cristiani S, Lipton JM, et al. J Leukoc Biol. 2000;67(2):233-9. PubMed 10670585
  3. Brzoska T, Luger TA, Maaser C, et al. Endocr Rev. 2008;29(5):581-602. PubMed 18612139
  4. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. Gastroenterology. 2008;134(1):166-78. PubMed 18061177
  5. Land SC. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. PubMed 22837805
  6. Elliott RJ, Szabo M, Wagner MJ, et al. J Invest Dermatol. 2004;122(4):1010-9. PubMed 15102092
  7. Kannengiesser K, Maaser C, Heidemann J, et al. Inflamm Bowel Dis. 2008;14(3):324-31. PubMed 18092346
  8. Singh M, Mukhopadhyay K. Antimicrob Agents Chemother. 2011;55(5):1920-9. PubMed 21282427
  9. Xiao B, Xu Z, Viennois E, et al. Mol Ther. 2017;25(7):1628-1640. PubMed 28143741
  10. Gravina AG, Pellegrino R, Durante T, et al. Cells. 2023;12(14). PubMed 37508552
  11. Viennois E, Ingersoll SA, Ayyadurai S, et al. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. PubMed 27458604
  12. Shao W, Chen R, Lin G, et al. Biomater Sci. 2021;10(1):227-242. PubMed 34846053
  13. Schaible EV, Steinsträßer A, Jahn-Eimermacher A, et al. PLoS One. 2013;8(8):e71056. PubMed 23940690
  14. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  15. Pharmaceutical Executive. FDA panel votes to loosen restrictions on four peptides (July 24, 2026). Source
  16. Regulatory Affairs Professionals Society. FDA advisory committee backs two controversial peptides (July 23, 2026). Source
  17. Kelley Drye & Warren LLP. FDA advisory committee recommends several peptides for compounding for various uses despite staff opposition: what stakeholders need to know (July 30, 2026). Source
  18. World Anti-Doping Agency. The 2026 Prohibited List, S0 Non-Approved Substances. Source